Today: 9 June 2026
IREN stock jumps 13% as bitcoin miners rebound; SEC filing adds fresh angle for traders

IREN stock jumps 13% as bitcoin miners rebound; SEC filing adds fresh angle for traders

NEW YORK, Jan 3, 2026, 14:10 ET — Market closed

  • IREN shares closed up 13.05% on Friday, outperforming the broader market on the first trading day of 2026.
  • Bitcoin-linked miners also posted double-digit gains, tracking a move in crypto and risk appetite.
  • A new SEC registration filing highlighted potential future share issuance under an employee incentive plan.

IREN Limited (IREN) shares jumped 13.05% on Friday to close at $42.70, their first session of 2026, as investors rotated back into high-volatility crypto and AI infrastructure-linked names.

The move matters because IREN has become a fast-moving proxy for two themes that can swing sharply on sentiment: bitcoin mining and powering AI computing. Friday’s bounce signaled renewed appetite for risk after a late-December slide in growth and speculative names.

The rally was not isolated. Larger listed bitcoin miners Marathon Digital (MARA), Riot Platforms (RIOT) and CleanSpark (CLSK) also ended sharply higher, pointing to a sector-wide bid rather than a single-stock catalyst.

Bitcoin was last near $90,000, leaving crypto-sensitive equities exposed to further swings in the token as the new trading week begins.

In broader markets, the Dow and S&P 500 ended higher on Friday as chipmakers led a rebound; the Philadelphia Semiconductor Index rose 4%. Joe Mazzola, head of trading and derivatives strategy at Charles Schwab, described a “buy the dip, sell the rip” mentality. Reuters

IREN also disclosed a new securities registration on Friday. A filing showed it registered 17.5 million ordinary shares for future issuance under its 2025 Omnibus Incentive Plan, adding a fresh datapoint for traders watching potential dilution.

The filing said the registration “does not constitute a current issuance” of shares. Form S-8 is a standard SEC registration statement companies use to cover stock awards under employee benefit plans; shares are only issued if awards are granted and exercised or vested.

IREN has drawn outsized attention over the past quarter as it pivots from bitcoin mining toward AI cloud and data center infrastructure. The company’s profile was lifted in November after Microsoft signed a $9.7 billion, five-year contract with IREN tied to access to Nvidia chips, Reuters reported at the time.

For the latest session, IREN traded between $38.10 and $42.99, with volume above 30 million shares, reflecting heavy participation despite the holiday-thinned start to the year.

Technically, traders will be watching whether the stock can hold above Friday’s lows near $38 and revisit the $43 area, which marked the session high. A break either way could set the tone for momentum flows when the market reopens on Monday.

Before the next session, macro risk is also back on the agenda. Reuters’ weekly outlook flagged U.S. employment data due Jan. 9 and consumer price inflation data due Jan. 13 as potential catalysts for rate expectations and equity volatility.

With growth valuations still sensitive to the rate path, any repricing of Federal Reserve expectations can quickly spill into high-beta names like IREN. Traders will also be watching for the start of fourth-quarter earnings season and any fresh company updates or financing moves that could reset expectations for its AI buildout.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next
Previous Story

Quantum computing stocks surge to start 2026: D-Wave, Rigetti, IonQ lead — what investors watch next

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom
Next Story

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Go toTop